About the ReSPECT™ Clinical Trials
Plus Therapeutics is a U.S. pharmaceutical company developing an innovative, targeted radiotherapeutic for adult & pediatric patients with rare & difficult-to-treat cancers. In the ongoing and planned ReSPECT™ Clinical Trials, the safety & effectiveness of an investigational therapy, REYOBIQ™ (rhenium Re186 obisbemeda), will be evaluated in patients with central nervous system (CNS) tumors such as leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers.
What Treatment is Being Studied in ReSPECT™?
The therapy is called REYOBIQ™ (rhenium Re186 obisbemeda), administered to the patient in either an inpatient or outpatient setting, depending on the tumor type. Click here to learn more about REYOBIQ™
What is REYOBIQ™?
REYOBIQ™ is an innovative, targeted radiotherapeutic for central nervous system (CNS) tumors.
It is designed and intended to deliver a high, precise dose of radiation directly to specific cancer cells while sparing normal, healthy cells.
Where to Go for More Information?
Your healthcare provider will assess your eligibility for participation in a ReSPECT™ Clinical Trial. To learn more, explore our clinical trial pages or patient cancer guide sections linked above.